

Applicant : Ruth Sager et al.
Serial No. : 09/617,174
Filed : July 17, 2000
Page : 3

Attorney's Docket No.: 00530-079003

REMARKS


Applicant hereby submits that the enclosures fulfill the requirements under 37 C.F.R. §1.821-1.825. The amendments in the specification merely insert the paper copy of the Sequence Listing and sequence identifiers in the specification. No new matter has been added.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 5 Sept 2002



Anita L. Meiklejohn, Ph.D.
Reg. No. 35,283

Fish & Richardson P.C.
225 Franklin Street
Boston, Massachusetts 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

“Version With Markings to Show Changes Made”

RECEIVED

SEP 12 2002

TECH CENTER 1600/2900

In the claims:

Claim 17 has been cancelled.

Claims 1, 3, and 4 have been amended as follows:

1. (Amended) An isolated nucleic acid molecule comprising the nucleotide sequence of nucleotides 451-914 of SEQ ID NO:1 [the nucleotide sequence set forth in Fig. 3 from nucleotide -506 to nucleotide -44, inclusive].

3. (Amended) The isolated nucleic acid molecule of claim 1, comprising the nucleotide sequence of nucleotides 914-957 of SEQ ID NO:1 [the nucleotide sequence set forth in Fig. 3 from nucleotide -956 to nucleotide -1, inclusive].

4. (Amended) The isolated nucleic acid molecule of claim 1, comprising the nucleotide sequence of nucleotides 1-1141 of SEQ ID NO:1 [the nucleotide sequence set forth in Fig. 3 from nucleotide -956 to nucleotide +184, inclusive].